Amodiaquine pharmacogenetics
Amodiaquine pharmacogenetics
复制标题
DOI：
10.2217/14622416.9.10.1385
复制
发表时间：
2008-10-01
期刊：
影响因子：
2.1
通讯作者：
Gil, Jose Pedro
中科院分区：
文献类型：
--
作者：
Gil, Jose Pedro
阿莫地喹是控制疟疾联合治疗新全球战略中的核心药物。阿莫地喹主要通过多态性 P450 亚型 CYP2C8 在肝脏代谢为其主要活性代谢物去乙基阿莫地喹。阿莫地喹会引起罕见但严重的副作用，以及相对常见的轻微副作用。预计这些至少部分与 CYP2C8 等位基因相关。阿莫地喹暴露人群的药物遗传学知识对于药物警戒问题非常重要，也是从个人医学角度未来实际应用的第一步。
Amodiaquine is a central drug in the new global strategy of combination therapies for the control of malaria. Amodiaquine is mainly metabolized hepatically towards its major active metabolite desethylamodiaquine, by the polymorphic P450 isoform CYP2C8. Amodiaquine is associated with rare but serious side effects, as well as with relatively frequent mild ones. These are expected to be at least partially related to CYP2C8 alleles. Pharmacogenetic knowledge of amodiaquine exposed populations is important for pharmacovigilance issues and in being a first step for future realistic applications from a personal medicine perspective.